REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and ...

在其他近期新闻中，Plus Therapeutics在临床和监管方面取得了重大进展。该公司宣布美国食品药品监督管理局 (FDA)授予其研究性治疗药物Rhenium (186Re) Obisbemeda用于肺癌患者脑膜转移的孤儿药资格。这一资格提供了潜在的市场独占权和税收抵免等好处，增强了公司的开发前景。Plus ...

Ian Everard warns of a looming precious metals supply crunch. He highlights manipulated markets, dwindling silver stocks, and ...

The American Cancer Society awarded its 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, renowned kidney cancer expert and ...

D. Boral Capital initiated coverage of Plus Therapeutics (PSTV) with a Buy rating and $9 price target Plus is advancing a unique approach in ...

近日，江西铜业股份有限公司向国家知识产权局申请了一项名为“一种从含铼废有机相中提取铼的方法”的专利，公开号为CN119614911A，申请日期定于2024年12月。这一消息引发了业界的广泛关注，尤其在铼的提取与回收技术上，该专利可能会成为一项具有重要意义的创新。

However, Mirarco also figures that billions of dollars in critical minerals were being left untapped. It calculated, as an ...

D. Boral Capital began coverage on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a research note released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $9.00 ...

For billions of years, Earth’s atmosphere lacked the oxygen necessary to sustain complex life. While scientists have long ...

Toxic tailings discarded at some 10,000 abandoned mines together with those currently being produced by 200 others in operation across Canada could hide a multi-billion-dollar market opportunity as de ...

After hours: March 18 at 7:58:50 PM EDT Loading Chart for PSTV ...